| 二肽基肽酶Ⅳ抑制剂辅助胰岛素治疗1型糖尿病的研究进展 |
| |
| 引用本文： | 袁梦瑚,顾鸣宇,谭月晴,高君伟.二肽基肽酶Ⅳ抑制剂辅助胰岛素治疗1型糖尿病的研究进展[J].现代药物与临床,2019,42(8):1663-1669. |
| |
| 作者姓名： | 袁梦瑚 顾鸣宇 谭月晴 高君伟 |
| |
| 作者单位： | 三峡大学人民医院·湖北省宜昌市第一人民医院, 湖北 宜昌 443000;上海交通大学附属第一人民医院 临床药学科, 上海 200080;三峡大学 药物制剂研究所, 湖北 宜昌 443000,上海交通大学附属第一人民医院 内分泌代谢科, 上海 200080,三峡大学人民医院·湖北省宜昌市第一人民医院, 湖北 宜昌 443000;上海交通大学附属第一人民医院 内分泌代谢科, 上海 200080,上海交通大学附属第一人民医院 临床药学科, 上海 200080 |
| |
| 摘 要： | 二肽基肽酶Ⅳ（DPP-4）抑制剂为一类在2型糖尿病中应用广泛的口服降糖药，其疗效确切、给药方便、总体耐受性好，但目前尚未被批准用于1型糖尿病。国内外相关文献表明在1型糖尿病患者体内DPP-4抑制剂可以辅助胰岛素改善血糖、保护胰岛β细胞功能、降低谷氨酸脱羧酶抗体（GADA）滴度、减少胰岛素剂量，且不增加低血糖风险和体质量。因此，DPP-4抑制剂可能可作为1型糖尿病患者胰岛素的辅助治疗，作用机制可能源于其抑制胰岛α细胞分泌胰高血糖素，通过免疫机制使胰岛β细胞免受摧毁。
|
| 关 键 词： | 二肽基肽酶Ⅳ（DPP-4）抑制剂 1型糖尿病 谷氨酸脱羧酶抗体 胰高血糖素 |
| 收稿时间： | 2019/2/20 0:00:00 |
Research progress on DPP-4 inhibitors as adjuvant therapy for insulin in treatment of type 1 diabetes mellitus |
| |
| UAN Menghu,GU Mingyu,TAN Yueqing and GAO Junwei.Research progress on DPP-4 inhibitors as adjuvant therapy for insulin in treatment of type 1 diabetes mellitus[J].Drugs & Clinic,2019,42(8):1663-1669. |
| |
| Authors: | UAN Menghu GU Mingyu TAN Yueqing and GAO Junwei |
| |
| Affiliation: | The People''s Hospital of China Three Gorges University, The First People''s Hospital of Yichang, Yichang 443000, China;Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China;Institute of Pharmaceutic Preparation, China Three Gorges University, Yichang 443000, China,Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China,The People''s Hospital of China Three Gorges University, The First People''s Hospital of Yichang, Yichang 443000, China;Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200080, China and Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China |
| |
| Abstract: | DPP-4 inhibitors, a class of effective, convenient and well-tolerated oral hypoglycemic drugs widely used in type 2 diabetes mellitus, have not been approved for type 1 diabetes mellitus yet. Referring to the relevant literatures at home and abroad, we found DPP-4 inhibitors may be an adjuvant therapy for insulin in patients with type 1 diabetes mellitus. They can assist insulin to improve blood glucose, protect function of islet beta cell, reduce GADA titer and decrease insulin dose in patients with type 1 diabetes, without increasing the risk of hypoglycemia and body weight. The mechanism may be that DPP-4 inhibitors can inhibit the secretion of glucagon by islet alpha cells and lessen the destruction of islet beta cells by immune mechanism. |
| |
| Keywords: | dipeptidyl peptidase-IV (DPP-4) inhibitors type 1 diabetes mellitus glutamic acid decarboxylase antibody glucagon |
|
| 点击此处可从《现代药物与临床》浏览原始摘要信息 |
|
点击此处可从《现代药物与临床》下载全文 |
|
